Roche halts some shipments of Sarepta’s Duchenne gene therapy outside U.S.

Taking stock of the drug industry, from the lab to the medicine chest

July 23, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Sebastien Bozon/AFP via Getty Images STAT+ | Roche halts some shipments of Sarepta's Duchenne gene therapy outside U.S. Roche sells Sarepta's gene therapy Elevidys outside the U.S., and said it was halting shipments to some countries amid safety concerns. By Andrew Joseph STAT+ | Solid tumors have challenged CAR-T developers. This biotech raised $216 million to test a new approach Dispatch Bio is developing a universal immunotherapy by trying to install a synthetic protein — called the "flare" antigen — on every cancer cell in a patient's body. By Angus Chen and Allison DeAngelis STAT+ | Small biotech Abivax scores major win with ulcerative colitis trials The drug, obefazimod, helped patients with the bowel disease enter remission. The company said it planned to file for approval next year. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser